Grantham Mayo Van Otterloo & Co. LLC Increases Stock Position in Haleon PLC Sponsored ADR $HLN

Grantham Mayo Van Otterloo & Co. LLC increased its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 13.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 888,839 shares of the company’s stock after purchasing an additional 103,601 shares during the period. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Haleon were worth $7,973,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of HLN. Golden State Wealth Management LLC lifted its position in shares of Haleon by 107.6% during the second quarter. Golden State Wealth Management LLC now owns 2,721 shares of the company’s stock worth $28,000 after acquiring an additional 1,410 shares in the last quarter. SOA Wealth Advisors LLC. grew its position in shares of Haleon by 60.5% in the third quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock valued at $28,000 after purchasing an additional 1,170 shares in the last quarter. Citizens National Bank Trust Department grew its position in shares of Haleon by 167.4% in the third quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock valued at $29,000 after purchasing an additional 2,051 shares in the last quarter. Atlantic Union Bankshares Corp raised its stake in shares of Haleon by 293.7% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after purchasing an additional 2,758 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares in the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HLN has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft downgraded shares of Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Haleon currently has an average rating of “Moderate Buy” and an average target price of $12.33.

Haleon Stock Down 0.1%

Shares of NYSE:HLN opened at $10.27 on Tuesday. The firm has a market capitalization of $45.71 billion, a PE ratio of 26.32 and a beta of 0.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. Haleon PLC Sponsored ADR has a 52-week low of $8.71 and a 52-week high of $11.42. The firm has a fifty day moving average of $10.50 and a 200 day moving average of $9.85.

Haleon Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Thursday, May 14th. Stockholders of record on Friday, April 10th will be given a dividend of $0.1307 per share. The ex-dividend date is Friday, April 10th. This represents a dividend yield of 251.0%. Haleon’s dividend payout ratio is 28.21%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.